publication venue for
- Rapid access rehabilitation after exacerbations of COPD – A qualitative study. 186:106532-106532. 2021
- A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm. 106568-106568. 2021
- Evaluating post-bronchodilator response in well-controlled paediatric severe asthma using hyperpolarised 129Xe-MRI: A pilot study. 180:106368-106368. 2021
- A comprehensive analysis of factors related to lung function in older adults: Cross-sectional findings from the Canadian Longitudinal Study on Aging. 173:106157-106157. 2020
- Randomized controlled trial of community-based, post-rehabilitation exercise in COPD. 174:106195-106195. 2020
- Sputum quantitative cytometry in patients with interstitial lung disease and chronic cough. 170:106067-106067. 2020
- Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. 156:20-25. 2019
- Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. 145:130-137. 2018
- Effects of exercise training on cognition in chronic obstructive pulmonary disease: A systematic review. 139:110-116. 2018
- Sputum plug selection under inverted microscopy improves microbial identification during exacerbations of airway diseases. 134:92-94. 2018
- Therapeutic targets in idiopathic pulmonary fibrosis. 131:49-57. 2017
- Informal caregiving in COPD: A systematic review of instruments and their measurement properties. 128:13-27. 2017
- Systemic inflammation and lung function: A longitudinal analysis. 111:54-59. 2016
- Corrigendum to “Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial” [Res Med 108 (2014) 41–49]. 109:146-146. 2015
- COST-effectiveness of salmeterol/fluticasone propionate combination (Advair®) in uncontrolled asthma in Canada. 108:1292-1302. 2014
- Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. 108:1023-1030. 2014
- Complement components as potential therapeutic targets for asthma treatment. 108:543-549. 2014
- Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. 108:181-188. 2014
- Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. 108:41-49. 2014
- A novel approach to long-term respiratory care: Results of a community-based post-rehabilitation maintenance program in COPD. 107:1210-1216. 2013
- Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. 107:656-664. 2013
- Comparison of changes in lung function measured by plethymography and IOS after bronchoprovocation. 107:503-510. 2013
- A simple method to derive speed for the endurance shuttle walk test. 106:1665-1670. 2012
- Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. 106:1487-1493. 2012
- Ciliary beating is depressed in nasal cilia from chronic obstructive pulmonary disease subjects. 106:1139-1147. 2012
- Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. 105:1836-1845. 2011
- Lipid and smoker’s inclusions in sputum macrophages in patients with airway diseases. 105:1691-1695. 2011
- Expiratory flows and airway inflammation in elderly asthmatic patients. 105:1284-1289. 2011
- Validation of an electronic version of the Mini Asthma Quality of Life Questionnaire. 104:658-667. 2010
- A simple and portable breathing circuit designed for ventilatory muscle endurance training (VMET). 103:1822-1827. 2009
- Impairments in balance discriminate fallers from non-fallers in COPD. 103:1885-1891. 2009
- Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. 103:1960-1968. 2009
- Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. 103:1623-1632. 2009
- Response to the Letter to the Editor. 103:1240-1241. 2009
- Safety, pharmacodynamics and pharmacokinetics of TPI 1020 in smokers with asthma. 103:1159-1166. 2009
- Patients may respond differently to paper and electronic versions of the same questionnaires. 103:932-934. 2009
- Duration of pulmonary rehabilitation to achieve a plateau in quality of life and walk test in COPD. 103:722-728. 2009
- Inspiratory muscle training in adults with chronic obstructive pulmonary disease: An update of a systematic review. 102:1715-1729. 2008
- Predictors of a more favourable response to combined therapy with salmeterol and fluticasone as initial maintenance therapy in asthma. 102:77-81. 2008
- Changing pattern of sputum cell counts during successive exacerbations of airway disease. 101:2217-2220. 2007
- Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. 101:308-316. 2007
- Self-care approaches to managing chronic obstructive pulmonary disease: A provincial survey. 100:1540-1546. 2006
- Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. 100:616-621. 2006
- Inspiratory muscle training in adults with chronic obstructive pulmonary disease: A systematic review. 99:1440-1458. 2005
- Once-daily ciclesonide 80 or 320μg for 12 weeks is safe and effective in patients with persistent asthma. 99:1275-1285. 2005
- Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. 99:553-558. 2005
-
Past, present and future—
- Measurement of agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians—A prospective study. 98:1195-1202. 2004
- An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. 98:1146-1154. 2004
- Self-administration and standardisation of the chronic respiratory questionnaire: a randomised trial in three German-speaking countries. 98:342-350. 2004
- Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. 97:242-249. 2003
- Decision-making by healthcare payers. 96:S31-S38. 2002
- The evolution of β2-agonists. 95:S2-S6. 2001
- Adding formoterol to budesonide in moderate asthma—health economic results from the FACET study. 95:505-512. 2001
- Measuring asthma control in group studies: do we need airway calibre and rescue β2-agonist use?. 95:319-323. 2001
- Amiodarone and the lung: wide variations in clinical practice. 94:1130-1131. 2000
- Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis. 93:75-78. 1999
- Evaluation of fluticasone propionate (500 μg day−1) administered either as dry powder via a Diskhaler® inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day−1) administered by pressurized inhaler. 87:609-620. 1993
- The effect of increasing doses of β-agonists on airflow in patients with chronic airflow limitation. 87:433-438. 1993
- Measuring functional status in chronic lung disease:conclusions from a randomized control trial. 85:17-21. 1991
- Measuring functional status in chronic lung disease: conclusions from a randomized control trial. 83:293-297. 1989